Cargando…

Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic

Ibrutinib revolutionized therapy for relapsed/refractory (R/R) mantle cell lymphoma (MCL). Real-world data on the outcome of unselected patients are still limited. We analyzed 77 R/R MCL patients receiving ibrutinib with at least one prior systemic anti-lymphoma therapy. After a median follow-up of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Obr, Ales, Benesova, Katerina, Janikova, Andrea, Mocikova, Heidi, Belada, David, Hruskova, Andrea, Vockova, Petra, Salek, David, Sykorova, Alice, Furst, Tomas, Malarikova, Diana, Papajik, Tomas, Trneny, Marek, Klener, Pavel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807478/ https://www.ncbi.nlm.nih.gov/pubmed/36369497 http://dx.doi.org/10.1007/s00277-022-05023-2

Ejemplares similares

Peripheral T-Cell Lymphomas Involving the Central Nervous System: A Report From the Czech Lymphoma Study Group Registry
por: Mocikova, Heidi, et al.
Publicado: (2022)

Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R‐CHOP
por: Procházka, Vít, et al.
Publicado: (2020)

A New Prognostic Score for Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: The Prognostic Role of Blood Monocyte and Lymphocyte Counts Is Absent
por: Procházka, Vít, et al.
Publicado: (2014)

P047: Predictive role of the Hodgkin lymphoma-associated cytokines: a prospective study of the Czech Hodgkin Study Group
por: Prochazka, Vit, et al.
Publicado: (2022)

Concurrent TP53 and CDKN2A Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy
por: Malarikova, Diana, et al.
Publicado: (2020)

COVID-19 in 96 Patients With Hematologic Disease: The First Single-center Experience From the Czech Republic
por: Čerňan, Martin, et al.
Publicado: (2021)

P104: Consolidation Therapy with Brentuximab Vedotin after Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Czech Republic.
por: Michalka, Jozef, et al.
Publicado: (2022)

Treatment of Relapsed/Refractory Hodgkin Lymphoma: Real-World Data from the Czech Republic and Slovakia
por: Král, Zdeněk, et al.
Publicado: (2019)

Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma
por: Broccoli, Alessandro, et al.
Publicado: (2018)

P023: PET2-adapted approach after 2 cycles of ABVD is comparable to 2 cycles of BEACOPP escalated and 2 cycles of ABVD and irradiation in early unfavorable Hodgkin lymphoma
por: Mocikova, Heidi, et al.
Publicado: (2022)

Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells
por: Otáhal, Pavel, et al.
Publicado: (2015)

COVID-19 in patients with chronic lymphocytic leukemia: a multicenter analysis by the Czech CLL study group
por: Šimkovič, Martin, et al.
Publicado: (2023)

Detailed Functional and Proteomic Characterization of Fludarabine Resistance in Mantle Cell Lymphoma Cells
por: Lorkova, Lucie, et al.
Publicado: (2015)

Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents
por: Klanova, Magdalena, et al.
Publicado: (2014)

Differential expression, localization and activity of MARCKS between mantle cell lymphoma and chronic lymphocytic leukemia
por: Vargova, J, et al.
Publicado: (2016)

Cryptococcal meningoencephalitis in patients with mantle cell lymphoma on ibrutinib
por: Sun, Kai, et al.
Publicado: (2018)

Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas
por: Jakša, Radek, et al.
Publicado: (2022)

Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma
por: Klener, Pavel
Publicado: (2019)

Breakthrough COVID-19 in Vaccinated Patients with Haematologic Malignancies—The First Single-Centre Experience from the Czech Republic
por: Čerňan, Martin, et al.
Publicado: (2022)

Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
por: Peterson, Derek, et al.
Publicado: (2014)

Ibrutinib Is Effective in the Treatment of Autoimmune Haemolytic Anaemia in Mantle Cell Lymphoma
por: Galinier, Aliénor, et al.
Publicado: (2017)

Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma
por: Zhao, Xiaohong, et al.
Publicado: (2017)

Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma
por: Zhao, Xiaohong, et al.
Publicado: (2021)

Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma
por: Li, Lingzhi, et al.
Publicado: (2022)

Ibrutinib: Implications for Use in the Treatment of Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
por: McNally, Gretchen Anne, et al.
Publicado: (2015)

Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma
por: Maruyama, Dai, et al.
Publicado: (2016)

Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma
por: Portell, Craig A., et al.
Publicado: (2022)

CD52 and OXPHOS—potential targets in ibrutinib-treated mantle cell lymphoma
por: Fuhr, Viktoria, et al.
Publicado: (2022)

A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia
por: Tucker, David L, et al.
Publicado: (2015)

Ibrutinib Caused Mediastinal Emphysema and Pneumothorax in the Treatment of a Patient with Mantle Cell Lymphoma
por: Tsutsumi, Yutaka, et al.
Publicado: (2019)

Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real‐world experience
por: Jeon, Young‐Woo, et al.
Publicado: (2019)

PB2072: EFFICACY AND SIDE EFFECTS OF IBRUTINIB IN RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA
por: Basturk, A., et al.
Publicado: (2022)

Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options
por: Vodicka, Prokop, et al.
Publicado: (2022)

Trends in the treatment and survival of heart failure patients: a nationwide population‐based study in the Czech Republic
por: Táborský, Milos, et al.
Publicado: (2021)

NR4A1 inhibition synergizes with ibrutinib in killing mantle cell lymphoma cells
por: Li, Yangguang, et al.
Publicado: (2017)

CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma
por: Mohanty, Atish, et al.
Publicado: (2016)

Diffuse Alveolar Hemorrhage Secondary to Ibrutinib Therapy in a Patient With Refractory Mantle Cell Lymphoma
por: Locke, Clifford B, et al.
Publicado: (2020)

A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma
por: Qualls, David, et al.
Publicado: (2022)

Adaptation and validation of the Physical Activity Questionnaire for Older Children (PAQ-C) among Czech children
por: Cuberek, Roman, et al.
Publicado: (2021)

Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study
por: Rule, S, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_j66ttdrgdvhn9ppvjls6bovm8g